

270.2

ARTICLE 8

270.3

SCHEDULING OF MARIJUANA

270.4 Section 1. Minnesota Statutes 2022, section 152.02, subdivision 2, is amended to read:

270.5 Subd. 2. **Schedule I.** (a) Schedule I consists of the substances listed in this subdivision.

270.6 (b) Opiates. Unless specifically excepted or unless listed in another schedule, any of the
270.7 following substances, including their analogs, isomers, esters, ethers, salts, and salts of
270.8 isomers, esters, and ethers, whenever the existence of the analogs, isomers, esters, ethers,
270.9 and salts is possible:

270.10 (1) acetylmethadol;

270.11 (2) allylprodine;

270.12 (3) alphacetylmethadol (except levo-alphacetylmethadol, also known as levomethadyl
270.13 acetate);

270.14 (4) alphameprodine;

270.15 (5) alphamethadol;

270.16 (6) alpha-methylfentanyl benzethidine;

270.17 (7) betacetylmethadol;

270.18 (8) betameprodine;

270.19 (9) betamethadol;

270.20 (10) betaprodine;

270.21 (11) clonitazene;

270.22 (12) dextromoramide;

270.23 (13) diampromide;

270.24 (14) diethylambutene;

270.25 (15) difenoxin;

270.26 (16) dimenoxadol;

270.27 (17) dimepheptanol;

270.28 (18) dimethylambutene;

271.1 (19) dioxaphetyl butyrate;

271.2 (20) dipipanone;

269.22

ARTICLE 8**SCHEDULING OF MARIJUANA**

269.24 Section 1. Minnesota Statutes 2022, section 152.02, subdivision 2, is amended to read:

269.25 Subd. 2. **Schedule I.** (a) Schedule I consists of the substances listed in this subdivision.

269.26 (b) Opiates. Unless specifically excepted or unless listed in another schedule, any of the
269.27 following substances, including their analogs, isomers, esters, ethers, salts, and salts of
269.28 isomers, esters, and ethers, whenever the existence of the analogs, isomers, esters, ethers,
269.29 and salts is possible:

269.30 (1) acetylmethadol;

270.1 (2) allylprodine;

270.2 (3) alphacetylmethadol (except levo-alphacetylmethadol, also known as levomethadyl
270.3 acetate);

270.4 (4) alphameprodine;

270.5 (5) alphamethadol;

270.6 (6) alpha-methylfentanyl benzethidine;

270.7 (7) betacetylmethadol;

270.8 (8) betameprodine;

270.9 (9) betamethadol;

270.10 (10) betaprodine;

270.11 (11) clonitazene;

270.12 (12) dextromoramide;

270.13 (13) diampromide;

270.14 (14) diethylambutene;

270.15 (15) difenoxin;

270.16 (16) dimenoxadol;

270.17 (17) dimepheptanol;

270.18 (18) dimethylambutene;

270.19 (19) dioxaphetyl butyrate;

270.20 (20) dipipanone;

| | | | |
|--------|---|--------|---|
| 271.3 | (21) ethylmethylthiambutene; | 270.21 | (21) ethylmethylthiambutene; |
| 271.4 | (22) etonitazene; | 270.22 | (22) etonitazene; |
| 271.5 | (23) etoxeridine; | 270.23 | (23) etoxeridine; |
| 271.6 | (24) furethidine; | 270.24 | (24) furethidine; |
| 271.7 | (25) hydroxypethidine; | 270.25 | (25) hydroxypethidine; |
| 271.8 | (26) ketobemidone; | 270.26 | (26) ketobemidone; |
| 271.9 | (27) levomoramide; | 270.27 | (27) levomoramide; |
| 271.10 | (28) levophenacylmorphan; | 271.1 | (28) levophenacylmorphan; |
| 271.11 | (29) 3-methylfentanyl; | 271.2 | (29) 3-methylfentanyl; |
| 271.12 | (30) acetyl-alpha-methylfentanyl; | 271.3 | (30) acetyl-alpha-methylfentanyl; |
| 271.13 | (31) alpha-methylthiofentanyl; | 271.4 | (31) alpha-methylthiofentanyl; |
| 271.14 | (32) benzylfentanyl beta-hydroxyfentanyl; | 271.5 | (32) benzylfentanyl beta-hydroxyfentanyl; |
| 271.15 | (33) beta-hydroxy-3-methylfentanyl; | 271.6 | (33) beta-hydroxy-3-methylfentanyl; |
| 271.16 | (34) 3-methylthiofentanyl; | 271.7 | (34) 3-methylthiofentanyl; |
| 271.17 | (35) thenylfentanyl; | 271.8 | (35) thenylfentanyl; |
| 271.18 | (36) thiofentanyl; | 271.9 | (36) thiofentanyl; |
| 271.19 | (37) para-fluorofentanyl; | 271.10 | (37) para-fluorofentanyl; |
| 271.20 | (38) morpheridine; | 271.11 | (38) morpheridine; |
| 271.21 | (39) 1-methyl-4-phenyl-4-propionoxypiperidine; | 271.12 | (39) 1-methyl-4-phenyl-4-propionoxypiperidine; |
| 271.22 | (40) noracymethadol; | 271.13 | (40) noracymethadol; |
| 271.23 | (41) norlevorphanol; | 271.14 | (41) norlevorphanol; |
| 271.24 | (42) normethadone; | 271.15 | (42) normethadone; |
| 271.25 | (43) norpiperidone; | 271.16 | (43) norpiperidone; |
| 271.26 | (44) 1-(2-phenylethyl)-4-phenyl-4-acetoxyppiperidine (PEPAP); | 271.17 | (44) 1-(2-phenylethyl)-4-phenyl-4-acetoxyppiperidine (PEPAP); |
| 271.27 | (45) phenadoxone; | 271.18 | (45) phenadoxone; |
| 272.1 | (46) phenampromide; | 271.19 | (46) phenampromide; |
| 272.2 | (47) phenomorphan; | 271.20 | (47) phenomorphan; |
| 272.3 | (48) phenoperidine; | 271.21 | (48) phenoperidine; |

| | | | |
|--------|---|--------|---|
| 272.4 | (49) piritramide; | 271.22 | (49) piritramide; |
| 272.5 | (50) proheptazine; | 271.23 | (50) proheptazine; |
| 272.6 | (51) properidine; | 271.24 | (51) properidine; |
| 272.7 | (52) propiram; | 271.25 | (52) propiram; |
| 272.8 | (53) racemoramide; | 271.26 | (53) racemoramide; |
| 272.9 | (54) tilidine; | 271.27 | (54) tilidine; |
| 272.10 | (55) trimeperidine; | 272.1 | (55) trimeperidine; |
| 272.11 | (56) N-(1-Phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl fentanyl); | 272.2 | (56) N-(1-Phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl fentanyl); |
| 272.12 | (57) 3,4-dichloro-N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-N- | 272.3 | (57) 3,4-dichloro-N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-N- |
| 272.13 | methylbenzamide(U47700); | 272.4 | methylbenzamide(U47700); |
| 272.14 | (58) N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide(furanyl fentanyl); | 272.5 | (58) N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide(furanyl fentanyl); |
| 272.15 | (59) 4-(4-bromophenyl)-4-dimethylamino-1-phenethylcyclohexanol (bromadol); | 272.6 | (59) 4-(4-bromophenyl)-4-dimethylamino-1-phenethylcyclohexanol (bromadol); |
| 272.16 | (60) N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide (Cyclopropyl | 272.7 | (60) N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide (Cyclopropyl |
| 272.17 | fentanyl); | 272.8 | fentanyl); |
| 272.18 | (61) N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide (butyryl fentanyl); | 272.9 | (61) N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide (butyryl fentanyl); |
| 272.19 | (62) 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45); | 272.10 | (62) 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45); |
| 272.20 | (63) N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide (cyclopentyl | 272.11 | (63) N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide (cyclopentyl |
| 272.21 | fentanyl); | 272.12 | fentanyl); |
| 272.22 | (64) N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide (isobutyryl fentanyl); | 272.13 | (64) N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide (isobutyryl fentanyl); |
| 272.23 | (65) N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide (valeryl fentanyl); | 272.14 | (65) N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide (valeryl fentanyl); |
| 272.24 | (66) N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide | 272.15 | (66) N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide |
| 272.25 | (para-chloroisobutyryl fentanyl); | 272.16 | (para-chloroisobutyryl fentanyl); |
| 272.26 | (67) N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide (para-fluorobutyryl | 272.17 | (67) N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide (para-fluorobutyryl |
| 272.27 | fentanyl); | 272.18 | fentanyl); |
| 272.28 | (68) N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide | 272.19 | (68) N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide |
| 272.29 | (para-methoxybutyryl fentanyl); | 272.20 | (para-methoxybutyryl fentanyl); |
| 273.1 | (69) N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetamide (ocfentanil); | 272.21 | (69) N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetamide (ocfentanil); |
| 273.2 | (70) N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide (4-fluoroisobutyryl | 272.22 | (70) N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide (4-fluoroisobutyryl |
| 273.3 | fentanyl or para-fluoroisobutyryl fentanyl); | 272.23 | fentanyl or para-fluoroisobutyryl fentanyl); |
| 273.4 | (71) N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide (acryl fentanyl or | 272.24 | (71) N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide (acryl fentanyl or |
| 273.5 | acryloylfentanyl); | 272.25 | acryloylfentanyl); |

273.6 (72) 2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide (methoxyacetyl
273.7 fentanyl);

273.8 (73) N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide (ortho-fluorofentanyl
273.9 or 2-fluorofentanyl);

273.10 (74) N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide
273.11 (tetrahydrofuryl fentanyl); and

273.12 (75) Fentanyl-related substances, their isomers, esters, ethers, salts and salts of isomers,
273.13 esters and ethers, meaning any substance not otherwise listed under another federal
273.14 Administration Controlled Substance Code Number or not otherwise listed in this section,
273.15 and for which no exemption or approval is in effect under section 505 of the Federal Food,
273.16 Drug, and Cosmetic Act, United States Code , title 21, section 355, that is structurally related
273.17 to fentanyl by one or more of the following modifications:

273.18 (i) replacement of the phenyl portion of the phenethyl group by any monocycle, whether
273.19 or not further substituted in or on the monocycle;

273.20 (ii) substitution in or on the phenethyl group with alkyl, alkenyl, alkoxy, hydroxyl, halo,
273.21 haloalkyl, amino, or nitro groups;

273.22 (iii) substitution in or on the piperidine ring with alkyl, alkenyl, alkoxy, ester, ether,
273.23 hydroxyl, halo, haloalkyl, amino, or nitro groups;

273.24 (iv) replacement of the aniline ring with any aromatic monocycle whether or not further
273.25 substituted in or on the aromatic monocycle; or

273.26 (v) replacement of the N-propionyl group by another acyl group.

273.27 (c) Opium derivatives. Any of the following substances, their analogs, salts, isomers,
273.28 and salts of isomers, unless specifically excepted or unless listed in another schedule,
273.29 whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:

273.30 (1) acetorphine;

273.31 (2) acetyldihydrocodeine;

274.1 (3) benzylmorphine;

274.2 (4) codeine methylbromide;

274.3 (5) codeine-n-oxide;

274.4 (6) cyprenorphine;

274.5 (7) desomorphine;

274.6 (8) dihydromorphine;

274.7 (9) drotebanol;

272.26 (72) 2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide (methoxyacetyl
272.27 fentanyl);

272.28 (73) N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide (ortho-fluorofentanyl
272.29 or 2-fluorofentanyl);

273.1 (74) N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide
273.2 (tetrahydrofuryl fentanyl); and

273.3 (75) Fentanyl-related substances, their isomers, esters, ethers, salts and salts of isomers,
273.4 esters and ethers, meaning any substance not otherwise listed under another federal
273.5 Administration Controlled Substance Code Number or not otherwise listed in this section,
273.6 and for which no exemption or approval is in effect under section 505 of the Federal Food,
273.7 Drug, and Cosmetic Act, United States Code , title 21, section 355, that is structurally related
273.8 to fentanyl by one or more of the following modifications:

273.9 (i) replacement of the phenyl portion of the phenethyl group by any monocycle, whether
273.10 or not further substituted in or on the monocycle;

273.11 (ii) substitution in or on the phenethyl group with alkyl, alkenyl, alkoxy, hydroxyl, halo,
273.12 haloalkyl, amino, or nitro groups;

273.13 (iii) substitution in or on the piperidine ring with alkyl, alkenyl, alkoxy, ester, ether,
273.14 hydroxyl, halo, haloalkyl, amino, or nitro groups;

273.15 (iv) replacement of the aniline ring with any aromatic monocycle whether or not further
273.16 substituted in or on the aromatic monocycle; or

273.17 (v) replacement of the N-propionyl group by another acyl group.

273.18 (c) Opium derivatives. Any of the following substances, their analogs, salts, isomers,
273.19 and salts of isomers, unless specifically excepted or unless listed in another schedule,
273.20 whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:

273.21 (1) acetorphine;

273.22 (2) acetyldihydrocodeine;

273.23 (3) benzylmorphine;

273.24 (4) codeine methylbromide;

273.25 (5) codeine-n-oxide;

273.26 (6) cyprenorphine;

273.27 (7) desomorphine;

273.28 (8) dihydromorphine;

273.29 (9) drotebanol;

| | | | |
|--------|---|--------|---|
| 274.8 | (10) etorphine; | 273.30 | (10) etorphine; |
| 274.9 | (11) heroin; | 274.1 | (11) heroin; |
| 274.10 | (12) hydromorphenol; | 274.2 | (12) hydromorphenol; |
| 274.11 | (13) methyldesorphine; | 274.3 | (13) methyldesorphine; |
| 274.12 | (14) methyldihydromorphine; | 274.4 | (14) methyldihydromorphine; |
| 274.13 | (15) morphine methylbromide; | 274.5 | (15) morphine methylbromide; |
| 274.14 | (16) morphine methylsulfonate; | 274.6 | (16) morphine methylsulfonate; |
| 274.15 | (17) morphine-n-oxide; | 274.7 | (17) morphine-n-oxide; |
| 274.16 | (18) myrophine; | 274.8 | (18) myrophine; |
| 274.17 | (19) nicocodeine; | 274.9 | (19) nicocodeine; |
| 274.18 | (20) nicomorphine; | 274.10 | (20) nicomorphine; |
| 274.19 | (21) normorphine; | 274.11 | (21) normorphine; |
| 274.20 | (22) pholcodine; and | 274.12 | (22) pholcodine; and |
| 274.21 | (23) thebacon. | 274.13 | (23) thebacon. |
| 274.22 | (d) Hallucinogens. Any material, compound, mixture or preparation which contains any | 274.14 | (d) Hallucinogens. Any material, compound, mixture or preparation which contains any |
| 274.23 | quantity of the following substances, their analogs, salts, isomers (whether optical, positional, | 274.15 | quantity of the following substances, their analogs, salts, isomers (whether optical, positional, |
| 274.24 | or geometric), and salts of isomers, unless specifically excepted or unless listed in another | 274.16 | or geometric), and salts of isomers, unless specifically excepted or unless listed in another |
| 274.25 | schedule, whenever the existence of the analogs, salts, isomers, and salts of isomers is | 274.17 | schedule, whenever the existence of the analogs, salts, isomers, and salts of isomers is |
| 274.26 | possible: | 274.18 | possible: |
| 274.27 | (1) methylenedioxy amphetamine; | 274.19 | (1) methylenedioxy amphetamine; |
| 274.28 | (2) methylenedioxymethamphetamine; | 274.20 | (2) methylenedioxymethamphetamine; |
| 275.1 | (3) methylenedioxy-N-ethylamphetamine (MDEA); | 274.21 | (3) methylenedioxy-N-ethylamphetamine (MDEA); |
| 275.2 | (4) n-hydroxy-methylenedioxyamphetamine; | 274.22 | (4) n-hydroxy-methylenedioxyamphetamine; |
| 275.3 | (5) 4-bromo-2,5-dimethoxyamphetamine (DOB); | 274.23 | (5) 4-bromo-2,5-dimethoxyamphetamine (DOB); |
| 275.4 | (6) 2,5-dimethoxyamphetamine (2,5-DMA); | 274.24 | (6) 2,5-dimethoxyamphetamine (2,5-DMA); |
| 275.5 | (7) 4-methoxyamphetamine; | 274.25 | (7) 4-methoxyamphetamine; |
| 275.6 | (8) 5-methoxy-3, 4-methylenedioxyamphetamine; | 274.26 | (8) 5-methoxy-3, 4-methylenedioxyamphetamine; |
| 275.7 | (9) alpha-ethyltryptamine; | 274.27 | (9) alpha-ethyltryptamine; |
| 275.8 | (10) bufotenine; | 274.28 | (10) bufotenine; |

| | | | |
|--------|--|--------|--|
| 275.9 | (11) diethyltryptamine; | 275.1 | (11) diethyltryptamine; |
| 275.10 | (12) dimethyltryptamine; | 275.2 | (12) dimethyltryptamine; |
| 275.11 | (13) 3,4,5-trimethoxyamphetamine; | 275.3 | (13) 3,4,5-trimethoxyamphetamine; |
| 275.12 | (14) 4-methyl-2, 5-dimethoxyamphetamine (DOM); | 275.4 | (14) 4-methyl-2, 5-dimethoxyamphetamine (DOM); |
| 275.13 | (15) ibogaine; | 275.5 | (15) ibogaine; |
| 275.14 | (16) lysergic acid diethylamide (LSD); | 275.6 | (16) lysergic acid diethylamide (LSD); |
| 275.15 | (17) mescaline; | 275.7 | (17) mescaline; |
| 275.16 | (18) parahexyl; | 275.8 | (18) parahexyl; |
| 275.17 | (19) N-ethyl-3-piperidyl benzilate; | 275.9 | (19) N-ethyl-3-piperidyl benzilate; |
| 275.18 | (20) N-methyl-3-piperidyl benzilate; | 275.10 | (20) N-methyl-3-piperidyl benzilate; |
| 275.19 | (21) psilocybin; | 275.11 | (21) psilocybin; |
| 275.20 | (22) psilocyn; | 275.12 | (22) psilocyn; |
| 275.21 | (23) tenocyclidine (TPCP or TCP); | 275.13 | (23) tenocyclidine (TPCP or TCP); |
| 275.22 | (24) N-ethyl-1-phenyl-cyclohexylamine (PCE); | 275.14 | (24) N-ethyl-1-phenyl-cyclohexylamine (PCE); |
| 275.23 | (25) 1-(1-phenylcyclohexyl) pyrrolidine (PCPy); | 275.15 | (25) 1-(1-phenylcyclohexyl) pyrrolidine (PCPy); |
| 275.24 | (26) 1-[1-(2-thienyl)cyclohexyl]-pyrrolidine (TCPy); | 275.16 | (26) 1-[1-(2-thienyl)cyclohexyl]-pyrrolidine (TCPy); |
| 275.25 | (27) 4-chloro-2,5-dimethoxyamphetamine (DOC); | 275.17 | (27) 4-chloro-2,5-dimethoxyamphetamine (DOC); |
| 275.26 | (28) 4-ethyl-2,5-dimethoxyamphetamine (DOET); | 275.18 | (28) 4-ethyl-2,5-dimethoxyamphetamine (DOET); |
| 275.27 | (29) 4-iodo-2,5-dimethoxyamphetamine (DOI); | 275.19 | (29) 4-iodo-2,5-dimethoxyamphetamine (DOI); |
| 276.1 | (30) 4-bromo-2,5-dimethoxyphenethylamine (2C-B); | 275.20 | (30) 4-bromo-2,5-dimethoxyphenethylamine (2C-B); |
| 276.2 | (31) 4-chloro-2,5-dimethoxyphenethylamine (2C-C); | 275.21 | (31) 4-chloro-2,5-dimethoxyphenethylamine (2C-C); |
| 276.3 | (32) 4-methyl-2,5-dimethoxyphenethylamine (2C-D); | 275.22 | (32) 4-methyl-2,5-dimethoxyphenethylamine (2C-D); |
| 276.4 | (33) 4-ethyl-2,5-dimethoxyphenethylamine (2C-E); | 275.23 | (33) 4-ethyl-2,5-dimethoxyphenethylamine (2C-E); |
| 276.5 | (34) 4-iodo-2,5-dimethoxyphenethylamine (2C-I); | 275.24 | (34) 4-iodo-2,5-dimethoxyphenethylamine (2C-I); |
| 276.6 | (35) 4-propyl-2,5-dimethoxyphenethylamine (2C-P); | 275.25 | (35) 4-propyl-2,5-dimethoxyphenethylamine (2C-P); |
| 276.7 | (36) 4-isopropylthio-2,5-dimethoxyphenethylamine (2C-T-4); | 275.26 | (36) 4-isopropylthio-2,5-dimethoxyphenethylamine (2C-T-4); |
| 276.8 | (37) 4-propylthio-2,5-dimethoxyphenethylamine (2C-T-7); | 275.27 | (37) 4-propylthio-2,5-dimethoxyphenethylamine (2C-T-7); |

| | | | |
|--------|--|--------|--|
| 276.9 | (38) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine | 276.1 | (38) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine |
| 276.10 | (2-CB-FLY); | 276.2 | (2-CB-FLY); |
| 276.11 | (39) bromo-benzodifuranyl-isopropylamine (Bromo-DragonFLY); | 276.3 | (39) bromo-benzodifuranyl-isopropylamine (Bromo-DragonFLY); |
| 276.12 | (40) alpha-methyltryptamine (AMT); | 276.4 | (40) alpha-methyltryptamine (AMT); |
| 276.13 | (41) N,N-diisopropyltryptamine (DiPT); | 276.5 | (41) N,N-diisopropyltryptamine (DiPT); |
| 276.14 | (42) 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT); | 276.6 | (42) 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT); |
| 276.15 | (43) 4-acetoxy-N,N-diethyltryptamine (4-AcO-DET); | 276.7 | (43) 4-acetoxy-N,N-diethyltryptamine (4-AcO-DET); |
| 276.16 | (44) 4-hydroxy-N-methyl-N-propyltryptamine (4-HO-MPT); | 276.8 | (44) 4-hydroxy-N-methyl-N-propyltryptamine (4-HO-MPT); |
| 276.17 | (45) 4-hydroxy-N,N-dipropyltryptamine (4-HO-DPT); | 276.9 | (45) 4-hydroxy-N,N-dipropyltryptamine (4-HO-DPT); |
| 276.18 | (46) 4-hydroxy-N,N-diallyltryptamine (4-HO-DALT); | 276.10 | (46) 4-hydroxy-N,N-diallyltryptamine (4-HO-DALT); |
| 276.19 | (47) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT); | 276.11 | (47) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT); |
| 276.20 | (48) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT); | 276.12 | (48) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT); |
| 276.21 | (49) 5-methoxy-alpha-methyltryptamine (5-MeO-AMT); | 276.13 | (49) 5-methoxy-alpha-methyltryptamine (5-MeO-AMT); |
| 276.22 | (50) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT); | 276.14 | (50) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT); |
| 276.23 | (51) 5-methylthio-N,N-dimethyltryptamine (5-MeS-DMT); | 276.15 | (51) 5-methylthio-N,N-dimethyltryptamine (5-MeS-DMT); |
| 276.24 | (52) 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT); | 276.16 | (52) 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT); |
| 276.25 | (53) 5-methoxy-alpha-ethyltryptamine (5-MeO-AET); | 276.17 | (53) 5-methoxy-alpha-ethyltryptamine (5-MeO-AET); |
| 276.26 | (54) 5-methoxy-N,N-dipropyltryptamine (5-MeO-DPT); | 276.18 | (54) 5-methoxy-N,N-dipropyltryptamine (5-MeO-DPT); |
| 276.27 | (55) 5-methoxy-N,N-diethyltryptamine (5-MeO-DET); | 276.19 | (55) 5-methoxy-N,N-diethyltryptamine (5-MeO-DET); |
| 277.1 | (56) 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT); | 276.20 | (56) 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT); |
| 277.2 | (57) methoxetamine (MXE); | 276.21 | (57) methoxetamine (MXE); |
| 277.3 | (58) 5-iodo-2-aminoindane (5-IAI); | 276.22 | (58) 5-iodo-2-aminoindane (5-IAI); |
| 277.4 | (59) 5,6-methylenedioxy-2-aminoindane (MDAI); | 276.23 | (59) 5,6-methylenedioxy-2-aminoindane (MDAI); |
| 277.5 | (60) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe); | 276.24 | (60) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe); |
| 277.6 | (61) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe); | 276.25 | (61) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe); |
| 277.7 | (62) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe); | 276.26 | (62) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe); |
| 277.8 | (63) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H); | 276.27 | (63) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H); |
| 277.9 | (64) 2-(4-Ethylthio-2,5-dimethoxyphenyl)ethanamine (2C-T-2); | 277.1 | (64) 2-(4-Ethylthio-2,5-dimethoxyphenyl)ethanamine (2C-T-2); |

277.10 (65) N,N-Dipropyltryptamine (DPT);
277.11 (66) 3-[1-(Piperidin-1-yl)cyclohexyl]phenol (3-HO-PCP);
277.12 (67) N-ethyl-1-(3-methoxyphenyl)cyclohexanamine (3-MeO-PCE);
277.13 (68) 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo);
277.14 (69) 1-[1-(4-methoxyphenyl)cyclohexyl]-piperidine (methoxydine, 4-MeO-PCP);
277.15 (70) 2-(2-Chlorophenyl)-2-(ethylamino)cyclohexan-1-one (N-Ethylnorketamine,
277.16 ethketamine, NENK);
277.17 (71) methylenedioxy-N,N-dimethylamphetamine (MDDMA);
277.18 (72) 3-(2-Ethyl(methyl)aminoethyl)-1H-indol-4-yl (4-AcO-MET); and
277.19 (73) 2-Phenyl-2-(methylamino)cyclohexanone (deschloroketamine).

277.20 (e) Peyote. All parts of the plant presently classified botanically as *Lophophora williamsii*
277.21 Lemaire, whether growing or not, the seeds thereof, any extract from any part of the plant,
277.22 and every compound, manufacture, salts, derivative, mixture, or preparation of the plant,
277.23 its seeds or extracts. The listing of peyote as a controlled substance in Schedule I does not
277.24 apply to the nondrug use of peyote in bona fide religious ceremonies of the American Indian
277.25 Church, and members of the American Indian Church are exempt from registration. Any
277.26 person who manufactures peyote for or distributes peyote to the American Indian Church,
277.27 however, is required to obtain federal registration annually and to comply with all other
277.28 requirements of law.

277.29 (f) Central nervous system depressants. Unless specifically excepted or unless listed in
277.30 another schedule, any material compound, mixture, or preparation which contains any
278.1 quantity of the following substances, their analogs, salts, isomers, and salts of isomers:
278.2 whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:

278.3 (1) mecloqualone;
278.4 (2) methaqualone;
278.5 (3) gamma-hydroxybutyric acid (GHB), including its esters and ethers;
278.6 (4) flunitrazepam;
278.7 (5) 2-(2-Methoxyphenyl)-2-(methylamino)cyclohexanone (2-MeO-2-deschloroketamine,
278.8 methoxyketamine);
278.9 (6) tianeptine;
278.10 (7) clonazolam;
278.11 (8) etizolam;

277.2 (65) N,N-Dipropyltryptamine (DPT);
277.3 (66) 3-[1-(Piperidin-1-yl)cyclohexyl]phenol (3-HO-PCP);
277.4 (67) N-ethyl-1-(3-methoxyphenyl)cyclohexanamine (3-MeO-PCE);
277.5 (68) 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo);
277.6 (69) 1-[1-(4-methoxyphenyl)cyclohexyl]-piperidine (methoxydine, 4-MeO-PCP);
277.7 (70) 2-(2-Chlorophenyl)-2-(ethylamino)cyclohexan-1-one (N-Ethylnorketamine,
277.8 ethketamine, NENK);
277.9 (71) methylenedioxy-N,N-dimethylamphetamine (MDDMA);
277.10 (72) 3-(2-Ethyl(methyl)aminoethyl)-1H-indol-4-yl (4-AcO-MET); and
277.11 (73) 2-Phenyl-2-(methylamino)cyclohexanone (deschloroketamine).

277.12 (e) Peyote. All parts of the plant presently classified botanically as *Lophophora williamsii*
277.13 Lemaire, whether growing or not, the seeds thereof, any extract from any part of the plant,
277.14 and every compound, manufacture, salts, derivative, mixture, or preparation of the plant,
277.15 its seeds or extracts. The listing of peyote as a controlled substance in Schedule I does not
277.16 apply to the nondrug use of peyote in bona fide religious ceremonies of the American Indian
277.17 Church, and members of the American Indian Church are exempt from registration. Any
277.18 person who manufactures peyote for or distributes peyote to the American Indian Church,
277.19 however, is required to obtain federal registration annually and to comply with all other
277.20 requirements of law.

277.21 (f) Central nervous system depressants. Unless specifically excepted or unless listed in
277.22 another schedule, any material compound, mixture, or preparation which contains any
277.23 quantity of the following substances, their analogs, salts, isomers, and salts of isomers:
277.24 whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:

277.25 (1) mecloqualone;
277.26 (2) methaqualone;
277.27 (3) gamma-hydroxybutyric acid (GHB), including its esters and ethers;
277.28 (4) flunitrazepam;
277.29 (5) 2-(2-Methoxyphenyl)-2-(methylamino)cyclohexanone (2-MeO-2-deschloroketamine,
277.30 methoxyketamine);
278.1 (6) tianeptine;
278.2 (7) clonazolam;
278.3 (8) etizolam;

| | | | |
|--------|---|--------|---|
| 278.12 | (9) flubromazolam; and | 278.4 | (9) flubromazolam; and |
| 278.13 | (10) flubromazepam. | 278.5 | (10) flubromazepam. |
| 278.14 | (g) Stimulants. Unless specifically excepted or unless listed in another schedule, any | 278.6 | (g) Stimulants. Unless specifically excepted or unless listed in another schedule, any |
| 278.15 | material compound, mixture, or preparation which contains any quantity of the following | 278.7 | material compound, mixture, or preparation which contains any quantity of the following |
| 278.16 | substances, their analogs, salts, isomers, and salts of isomers whenever the existence of the | 278.8 | substances, their analogs, salts, isomers, and salts of isomers whenever the existence of the |
| 278.17 | analogs, salts, isomers, and salts of isomers is possible: | 278.9 | analogs, salts, isomers, and salts of isomers is possible: |
| 278.18 | (1) aminorex; | 278.10 | (1) aminorex; |
| 278.19 | (2) cathinone; | 278.11 | (2) cathinone; |
| 278.20 | (3) fenethylline; | 278.12 | (3) fenethylline; |
| 278.21 | (4) methcathinone; | 278.13 | (4) methcathinone; |
| 278.22 | (5) methylaminorex; | 278.14 | (5) methylaminorex; |
| 278.23 | (6) N,N-dimethylamphetamine; | 278.15 | (6) N,N-dimethylamphetamine; |
| 278.24 | (7) N-benzylpiperazine (BZP); | 278.16 | (7) N-benzylpiperazine (BZP); |
| 278.25 | (8) methylmethcathinone (mephedrone); | 278.17 | (8) methylmethcathinone (mephedrone); |
| 278.26 | (9) 3,4-methylenedioxy-N-methylcathinone (methylone); | 278.18 | (9) 3,4-methylenedioxy-N-methylcathinone (methylone); |
| 278.27 | (10) methoxymethcathinone (methedrone); | 278.19 | (10) methoxymethcathinone (methedrone); |
| 278.28 | (11) methylenedioxypyrovalerone (MDPV); | 278.20 | (11) methylenedioxypyrovalerone (MDPV); |
| 279.1 | (12) 3-fluoro-N-methylcathinone (3-FMC); | 278.21 | (12) 3-fluoro-N-methylcathinone (3-FMC); |
| 279.2 | (13) methyllethcathinone (MEC); | 278.22 | (13) methyllethcathinone (MEC); |
| 279.3 | (14) 1-benzofuran-6-ylpropan-2-amine (6-APB); | 278.23 | (14) 1-benzofuran-6-ylpropan-2-amine (6-APB); |
| 279.4 | (15) dimethylmethcathinone (DMMC); | 278.24 | (15) dimethylmethcathinone (DMMC); |
| 279.5 | (16) fluoroamphetamine; | 278.25 | (16) fluoroamphetamine; |
| 279.6 | (17) fluoromethamphetamine; | 278.26 | (17) fluoromethamphetamine; |
| 279.7 | (18) α -methylaminobutyrophenone (MABP or buphedrone); | 278.27 | (18) α -methylaminobutyrophenone (MABP or buphedrone); |
| 279.8 | (19) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone); | 278.28 | (19) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone); |
| 279.9 | (20) 2-(methylamino)-1-(4-methylphenyl)butan-1-one (4-MEMABP or BZ-6378); | 279.1 | (20) 2-(methylamino)-1-(4-methylphenyl)butan-1-one (4-MEMABP or BZ-6378); |
| 279.10 | (21) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl) pentan-1-one (naphthylpyrovalerone or | 279.2 | (21) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl) pentan-1-one (naphthylpyrovalerone or |
| 279.11 | naphyrone); | 279.3 | naphyrone); |
| 279.12 | (22) (alpha-pyrrolidinopentiophenone (alpha-PVP); | 279.4 | (22) (alpha-pyrrolidinopentiophenone (alpha-PVP); |

279.13 (23) (RS)-1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-hexanone (4-Me-PHP or MPHP);
 279.14 (24) 2-(1-pyrrolidinyl)-hexanophenone (Alpha-PHP);
 279.15 (25) 4-methyl-N-ethylcathinone (4-MEC);
 279.16 (26) 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP);
 279.17 (27) 2-(methylamino)-1-phenylpentan-1-one (pentedrone);
 279.18 (28) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentyline);
 279.19 (29) 4-fluoro-N-methylcathinone (4-FMC);
 279.20 (30) 3,4-methylenedioxy-N-ethylcathinone (ethylone);
 279.21 (31) alpha-pyrrolidinobutriophenone (α -PBP);
 279.22 (32) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB);
 279.23 (33) 1-phenyl-2-(1-pyrrolidinyl)-1-heptanone (PV8);
 279.24 (34) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran (6-APDB);
 279.25 (35) 4-methyl-alpha-ethylaminopentiophenone (4-MEAPP);
 279.26 (36) 4'-chloro-alpha-pyrrolidinopropiophenone (4'-chloro-PPP);
 279.27 (37) 1-(1,3-Benzodioxol-5-yl)-2-(dimethylamino)butan-1-one (dibutylone, bk-DMBDB);
 280.1 (38) 1-(3-chlorophenyl) piperazine (meta-chlorophenylpiperazine or mCPP);
 280.2 (39) 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one (N-ethylpentyline, ephylone);
 280.3 and
 280.4 (40) any other substance, except bupropion or compounds listed under a different
 280.5 schedule, that is structurally derived from 2-aminopropan-1-one by substitution at the
 280.6 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the
 280.7 compound is further modified in any of the following ways:
 280.8 (i) by substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy,
 280.9 haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring
 280.10 system by one or more other univalent substituents;
 280.11 (ii) by substitution at the 3-position with an acyclic alkyl substituent;
 280.12 (iii) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or
 280.13 methoxybenzyl groups; or
 280.14 (iv) by inclusion of the 2-amino nitrogen atom in a cyclic structure.
 280.15 (h) Marijuana, tetrahydrocannabinols, and synthetic cannabinoids. Unless specifically
 280.16 excepted or unless listed in another schedule, any natural or synthetic material, compound,

279.5 (23) (RS)-1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-hexanone (4-Me-PHP or MPHP);
 279.6 (24) 2-(1-pyrrolidinyl)-hexanophenone (Alpha-PHP);
 279.7 (25) 4-methyl-N-ethylcathinone (4-MEC);
 279.8 (26) 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP);
 279.9 (27) 2-(methylamino)-1-phenylpentan-1-one (pentedrone);
 279.10 (28) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentyline);
 279.11 (29) 4-fluoro-N-methylcathinone (4-FMC);
 279.12 (30) 3,4-methylenedioxy-N-ethylcathinone (ethylone);
 279.13 (31) alpha-pyrrolidinobutriophenone (α -PBP);
 279.14 (32) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB);
 279.15 (33) 1-phenyl-2-(1-pyrrolidinyl)-1-heptanone (PV8);
 279.16 (34) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran (6-APDB);
 279.17 (35) 4-methyl-alpha-ethylaminopentiophenone (4-MEAPP);
 279.18 (36) 4'-chloro-alpha-pyrrolidinopropiophenone (4'-chloro-PPP);
 279.19 (37) 1-(1,3-Benzodioxol-5-yl)-2-(dimethylamino)butan-1-one (dibutylone, bk-DMBDB);
 279.20 (38) 1-(3-chlorophenyl) piperazine (meta-chlorophenylpiperazine or mCPP);
 279.21 (39) 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one (N-ethylpentyline, ephylone);
 279.22 and
 279.23 (40) any other substance, except bupropion or compounds listed under a different
 279.24 schedule, that is structurally derived from 2-aminopropan-1-one by substitution at the
 279.25 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the
 279.26 compound is further modified in any of the following ways:
 279.27 (i) by substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy,
 279.28 haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring
 279.29 system by one or more other univalent substituents;
 280.1 (ii) by substitution at the 3-position with an acyclic alkyl substituent;
 280.2 (iii) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or
 280.3 methoxybenzyl groups; or
 280.4 (iv) by inclusion of the 2-amino nitrogen atom in a cyclic structure.
 280.5 (h) Marijuana, tetrahydrocannabinols, and synthetic cannabinoids. Unless specifically
 280.6 excepted or unless listed in another schedule, any natural or synthetic material, compound,

280.17 mixture, or preparation that contains any quantity of the following substances, their analogs, isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of the isomers, esters, ethers, or salts is possible:

280.20 (1) marijuana;

280.21 (2) tetrahydrocannabinols naturally contained in a plant of the genus Cannabis, except that tetrahydrocannabinols do not include any material, compound, mixture, or preparation that qualifies as industrial hemp as defined in section 18K.02, subdivision 3; synthetic equivalents of the substances contained in the cannabis plant or in the resinous extractives of the plant; or synthetic substances with similar chemical structure and pharmacological activity to those substances contained in the plant or resinous extract, including, but not limited to, 1 cis or trans tetrahydrocannabinol, 6 cis or trans tetrahydrocannabinol, and 3,4 eis or trans tetrahydrocannabinol;

280.29 (3) (h) Synthetic cannabinoids, including the following substances:

280.30 (A) (1) Naphthoylindoles, which are any compounds containing a 3-(1-naphthoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent. Examples of naphthoylindoles include, but are not limited to:

281.4 (A) (i) 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM-678);

281.5 (B) (ii) 1-Butyl-3-(1-naphthoyl)indole (JWH-073);

281.6 (C) (iii) 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081);

281.7 (D) (iv) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);

281.8 (E) (v) 1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015);

281.9 (F) (vi) 1-Hexyl-3-(1-naphthoyl)indole (JWH-019);

281.10 (G) (vii) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);

281.11 (H) (viii) 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210);

281.12 (I) (ix) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);

281.13 (J) (x) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201).

281.14 (H) (2) Naphthylmethylindoles, which are any compounds containing a 1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent. Examples of naphthylmethylindoles include, but are not limited to:

280.7 mixture, or preparation that contains any quantity of the following substances, their analogs, isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of the isomers, esters, ethers, or salts is possible:

280.10 (1) marijuana;

280.11 (2) tetrahydrocannabinols naturally contained in a plant of the genus Cannabis, except that tetrahydrocannabinols do not include any material, compound, mixture, or preparation that qualifies as industrial hemp as defined in section 18K.02, subdivision 3; synthetic equivalents of the substances contained in the cannabis plant or in the resinous extractives of the plant; or synthetic substances with similar chemical structure and pharmacological activity to those substances contained in the plant or resinous extract, including, but not limited to, 1 cis or trans tetrahydrocannabinol, 6 cis or trans tetrahydrocannabinol, and 3,4 eis or trans tetrahydrocannabinol;

280.19 (3) (h) Synthetic Artificial cannabinoids, including the following substances:

280.20 (A) (1) Naphthoylindoles, which are any compounds containing a 3-(1-naphthoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent. Examples of naphthoylindoles include, but are not limited to:

280.26 (A) (i) 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM-678);

280.27 (B) (ii) 1-Butyl-3-(1-naphthoyl)indole (JWH-073);

280.28 (C) (iii) 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081);

280.29 (D) (iv) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);

280.30 (E) (v) 1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015);

280.31 (F) (vi) 1-Hexyl-3-(1-naphthoyl)indole (JWH-019);

281.1 (G) (vii) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);

281.2 (H) (viii) 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210);

281.3 (I) (ix) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);

281.4 (J) (x) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201).

281.5 (H) (2) Naphthylmethylindoles, which are any compounds containing a 1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent. Examples of naphthylmethylindoles include, but are not limited to:

281.20 ~~(A)~~(i) 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane (JWH-175);
 281.21 ~~(B)~~(ii) 1-Pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methane (JWH-184).

281.22 ~~(iii)~~(3) Naphthoylpyrroles, which are any compounds containing a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the pyrrole ring to any extent, whether or not substituted in the naphthyl ring to any extent. Examples of naphthoylpyrroles include, but are not limited to,
 281.27 (5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone (JWH-307).

281.29 ~~(iv)~~(4) Naphthylmethylindenes, which are any compounds containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indene ring to any extent, whether or not substituted in the naphthyl ring to any extent. Examples of naphthylemethylindenes include, but are not limited to,
 282.4 E-1-[1-(1-naphthalenylmethylene)-1H-inden-3-yl]pentane (JWH-176).

282.5 ~~(v)~~(5) Phenylacetylindoles, which are any compounds containing a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent, whether or not substituted in the phenyl ring to any extent. Examples of phenylacetylindoles include, but are not limited to:
 282.11 ~~(A)~~(i) 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8);
 282.12 ~~(B)~~(ii) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);
 282.13 ~~(C)~~(iii) 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251);
 282.14 ~~(D)~~(iv) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).

282.15 ~~(vi)~~(6) Cyclohexylphenols, which are compounds containing a 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not substituted in the cyclohexyl ring to any extent. Examples of cyclohexylphenols include, but are not limited to:
 282.21 ~~(A)~~(i) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47,497);
 282.22 ~~(B)~~(ii) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol
 282.23 (Cannabicyclohexanol or CP 47,497 C8 homologue);

281.11 ~~(A)~~(i) 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane (JWH-175);
 281.12 ~~(B)~~(ii) 1-Pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methane (JWH-184).

281.13 ~~(iii)~~(3) Naphthoylpyrroles, which are any compounds containing a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the pyrrole ring to any extent, whether or not substituted in the naphthyl ring to any extent. Examples of naphthoylpyrroles include, but are not limited to,
 281.19 (5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone (JWH-307).

281.20 ~~(iv)~~(4) Naphthylmethylindenes, which are any compounds containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indene ring to any extent, whether or not substituted in the naphthyl ring to any extent. Examples of naphthylemethylindenes include, but are not limited to,
 281.26 E-1-[1-(1-naphthalenylmethylene)-1H-inden-3-yl]pentane (JWH-176).

281.27 ~~(v)~~(5) Phenylacetylindoles, which are any compounds containing a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent, whether or not substituted in the phenyl ring to any extent. Examples of phenylacetylindoles include, but are not limited to:
 281.32 (5-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8);
 282.1 ~~(B)~~(ii) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);
 282.2 ~~(C)~~(iii) 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251);
 282.3 ~~(D)~~(iv) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).

282.4 ~~(vi)~~(6) Cyclohexylphenols, which are compounds containing a 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not substituted in the cyclohexyl ring to any extent. Examples of cyclohexylphenols include, but are not limited to:
 282.10 ~~(A)~~(i) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47,497);
 282.11 ~~(B)~~(ii) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol
 282.12 (Cannabicyclohexanol or CP 47,497 C8 homologue);

282.24 ~~(E)~~(iii) 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]
 282.25 -phenol (CP 55,940).

282.26 ~~(vii)~~(7) Benzoylindoles, which are any compounds containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. Examples of benzoylindoles include, but are not limited to:

282.32 ~~(A)~~(i) 1-Pentyl-3-(4-methoxybenzoyl)indole (RCS-4);

283.1 ~~(B)~~(ii) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694);

283.2 ~~(C)~~(iii) (4-methoxyphenyl-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone
 283.3 (WIN 48,098 or Pravadoline).

283.4 ~~(viii)~~(8) Others specifically named:

283.5 ~~(A)~~(i) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
 283.6 -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (HU-210);

283.7 ~~(B)~~(ii) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
 283.8 -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (Dexanabinol or HU-211);

283.9 ~~(C)~~(iii) 2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]
 283.10 -1,4-benzoxazin-6-yl-1-naphthalenylmethanone (WIN 55,212-2);

283.11 ~~(D)~~(iv) (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144);

283.12 ~~(E)~~(v) (1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
 283.13 (XLR-11);

283.14 ~~(F)~~(vi) 1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3-carboxamide
 283.15 (AKB-48(APINACA));

283.16 ~~(G)~~(vii) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide
 283.17 (5-Fluoro-AKB-48);

283.18 ~~(H)~~(viii) 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22);

283.19 ~~(I)~~(ix) 8-quinolinyl ester-1-(5-fluoropentyl)-1H-indole-3-carboxylic acid (5-Fluoro
 283.20 PB-22);

283.21 ~~(J)~~(x) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole-3-carboxamide
 283.22 (AB-PINACA);

283.23 ~~(K)~~(xi) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-
 283.24 1H-indazole-3-carboxamide (AB-FUBINACA);

282.13 ~~(E)~~(iii) 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]
 282.14 -phenol (CP 55,940).

282.15 ~~(vii)~~(7) Benzoylindoles, which are any compounds containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. Examples of benzoylindoles include, but are not limited to:

282.21 ~~(A)~~(i) 1-Pentyl-3-(4-methoxybenzoyl)indole (RCS-4);

282.22 ~~(B)~~(ii) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694);

282.23 ~~(C)~~(iii) (4-methoxyphenyl-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone
 282.24 (WIN 48,098 or Pravadoline).

282.25 ~~(viii)~~(8) Others specifically named:

282.26 ~~(A)~~(i) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
 282.27 -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (HU-210);

282.28 ~~(B)~~(ii) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
 282.29 -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (Dexanabinol or HU-211);

282.30 ~~(C)~~(iii) 2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]
 282.31 -1,4-benzoxazin-6-yl-1-naphthalenylmethanone (WIN 55,212-2);

283.1 ~~(D)~~(iv) (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144);

283.2 ~~(E)~~(v) (1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
 283.3 (XLR-11);

283.4 ~~(F)~~(vi) 1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3-carboxamide
 283.5 (AKB-48(APINACA));

283.6 ~~(G)~~(vii) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide
 283.7 (5-Fluoro-AKB-48);

283.8 ~~(H)~~(viii) 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22);

283.9 ~~(I)~~(ix) 8-quinolinyl ester-1-(5-fluoropentyl)-1H-indole-3-carboxylic acid (5-Fluoro
 283.10 PB-22);

283.11 ~~(J)~~(x) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole-3-carboxamide
 283.12 (AB-PINACA);

283.13 ~~(K)~~(xi) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-
 283.14 1H-indazole-3-carboxamide (AB-FUBINACA);

283.25 ~~(E)~~(xii) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide(AB-CHMINACA);

283.27 ~~(M)~~(xiii) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (5-fluoro-AMB);

283.29 ~~(N)~~(xiv) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl) methanone (THJ-2201);

284.1 ~~(O)~~(xv) (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone (FUBIMINA);

284.3 ~~(P)~~(xvi) (7-methoxy-1-(2-morpholinoethyl)-N-((1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl)-1H-indole-3-carboxamide (MN-25 or UR-12);

284.5 ~~(Q)~~(xvii) (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5-fluoro-ABICA);

284.7 ~~(R)~~(xviii) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide;

284.9 ~~(S)~~(xix) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide;

284.11 ~~(T)~~(xx) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate;

284.13 ~~(U)~~(xxi) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (MAB-CHMINACA);

284.15 ~~(V)~~(xxii) N-(1-Amino-3,3-dimethyl-1-oxo-2-butanyl)-1-pentyl-1H-indazole-3-carboxamide (ADB-PINACA);

284.18 ~~(W)~~(xxiii) methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate (FUB-AMB);

284.19 ~~(X)~~(xxiv) N-[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl]-1-(cyclohexylmethyl)-1H-Indazole-3-carboxamide. (APP-CHMINACA);

284.22 ~~(Y)~~(xxv) quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FUB-PB-22); and

284.23 ~~(Z)~~(xxvi) methyl N-[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]valinate (MMB-CHMICA).

284.25 ~~(aa)~~(9) Additional substances specifically named:

284.26 ~~(A)~~(i) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1

284.27 H-pyrrolo[2,3-B]pyridine-3-carboxamide (5F-CUMYL-P7AICA);

284.28 ~~(B)~~(ii) 1-(4-cyanobutyl)-N-(2- phenylpropan-2-yl)-1 H-indazole-3-carboxamide

284.29 (4-CN-Cumyl-Butinaca);

283.15 ~~(E)~~(xii) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide(AB-CHMINACA);

283.17 ~~(M)~~(xiii) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-

283.18 methylbutanoate (5-fluoro-AMB);

283.19 ~~(N)~~(xiv) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl) methanone (THJ-2201);

283.20 ~~(O)~~(xv) (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone (FUBIMINA);

283.22 ~~(P)~~(xvi) (7-methoxy-1-(2-morpholinoethyl)-N-((1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl)-1H-indole-3-carboxamide (MN-25 or UR-12);

283.24 ~~(Q)~~(xvii) (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5-fluoro-ABICA);

283.26 ~~(R)~~(xviii) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide;

283.28 ~~(S)~~(xix) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide;

283.30 ~~(T)~~(xx) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate;

284.1 ~~(U)~~(xxi) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (MAB-CHMINACA);

284.3 ~~(V)~~(xxii) N-(1-Amino-3,3-dimethyl-1-oxo-2-butanyl)-1-pentyl-1H-indazole-3-carboxamide (ADB-PINACA);

284.6 ~~(W)~~(xxiii) methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate (FUB-AMB);

284.7 ~~(X)~~(xxiv)

284.8 N-[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl]-1-(cyclohexylmethyl)-1H-Indazole-3-carboxamide. (APP-CHMINACA);

284.10 ~~(Y)~~(xxv) quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FUB-PB-22); and

284.11 ~~(Z)~~(xxvi) methyl N-[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]valinate (MMB-CHMICA).

284.13 ~~(aa)~~(9) Additional substances specifically named:

284.14 ~~(A)~~(i) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1

284.15 H-pyrrolo[2,3-B]pyridine-3-carboxamide (5F-CUMYL-P7AICA);

284.16 ~~(B)~~(ii) 1-(4-cyanobutyl)-N-(2- phenylpropan-2-yl)-1 H-indazole-3-carboxamide

284.17 (4-CN-Cumyl-Butinaca);

284.30 ~~(E)~~(iii) naphthalen-1-yl-1-(5-fluoropentyl)-1-H-indole-3-carboxylate (NM2201;
 284.31 CBL2201);

285.1 ~~(D)~~(iv) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1
 285.2 H-indazole-3-carboxamide (5F-ABPINACA);

285.3 ~~(E)~~(v) methyl-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate
 285.4 (MDMB CHMICA);

285.5 ~~(F)~~(vi) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate
 285.6 (5F-ADB; 5F-MDMB-PINACA); and

285.7 ~~(G)~~(vii) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)
 285.8 1H-indazole-3-carboxamide (ADB-FUBINACA).

285.9 (i) A controlled substance analog, to the extent that it is implicitly or explicitly intended
 285.10 for human consumption.

285.11 **EFFECTIVE DATE.** This section is effective the day following final enactment.

285.12 Sec. 2. Minnesota Statutes 2022, section 152.02, subdivision 4, is amended to read:

285.13 Subd. 4. **Schedule III.** (a) Schedule III consists of the substances listed in this subdivision.

285.14 (b) Stimulants. Unless specifically excepted or unless listed in another schedule, any
 285.15 material, compound, mixture, or preparation which contains any quantity of the following
 285.16 substances having a potential for abuse associated with a stimulant effect on the central
 285.17 nervous system, including its salts, isomers, and salts of such isomers whenever the existence
 285.18 of such salts, isomers, and salts of isomers is possible within the specific chemical
 285.19 designation:

285.20 (1) benzphetamine;
 285.21 (2) chlorphentermine;
 285.22 (3) clortermine;
 285.23 (4) phendimetrazine.

285.24 (c) Depressants. Unless specifically excepted or unless listed in another schedule, any
 285.25 material, compound, mixture, or preparation which contains any quantity of the following
 285.26 substances having a potential for abuse associated with a depressant effect on the central
 285.27 nervous system:

285.28 (1) any compound, mixture, or preparation containing amobarbital, secobarbital,
 285.29 pentobarbital or any salt thereof and one or more other active medicinal ingredients which
 285.30 are not listed in any schedule;

284.18 ~~(E)~~(iii) naphthalen-1-yl-1-(5-fluoropentyl)-1-H-indole-3-carboxylate (NM2201;
 284.19 CBL2201);

284.20 ~~(D)~~(iv) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1
 284.21 H-indazole-3-carboxamide (5F-ABPINACA);

284.22 ~~(E)~~(v) methyl-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate
 284.23 (MDMB CHMICA);

284.24 ~~(F)~~(vi) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate
 284.25 (5F-ADB; 5F-MDMB-PINACA); and

284.26 ~~(G)~~(vii) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)
 284.27 1H-indazole-3-carboxamide (ADB-FUBINACA).

284.28 (i) A controlled substance analog, to the extent that it is implicitly or explicitly intended
 284.29 for human consumption.

284.30 **EFFECTIVE DATE.** This section is effective the day following final enactment.

285.1 Sec. 2. Minnesota Statutes 2022, section 152.02, subdivision 4, is amended to read:

285.2 Subd. 4. **Schedule III.** (a) Schedule III consists of the substances listed in this subdivision.

285.3 (b) Stimulants. Unless specifically excepted or unless listed in another schedule, any
 285.4 material, compound, mixture, or preparation which contains any quantity of the following
 285.5 substances having a potential for abuse associated with a stimulant effect on the central
 285.6 nervous system, including its salts, isomers, and salts of such isomers whenever the existence
 285.7 of such salts, isomers, and salts of isomers is possible within the specific chemical
 285.8 designation:

285.9 (1) benzphetamine;
 285.10 (2) chlorphentermine;
 285.11 (3) clortermine;
 285.12 (4) phendimetrazine.

285.13 (c) Depressants. Unless specifically excepted or unless listed in another schedule, any
 285.14 material, compound, mixture, or preparation which contains any quantity of the following
 285.15 substances having a potential for abuse associated with a depressant effect on the central
 285.16 nervous system:

285.17 (1) any compound, mixture, or preparation containing amobarbital, secobarbital,
 285.18 pentobarbital or any salt thereof and one or more other active medicinal ingredients which
 285.19 are not listed in any schedule;

286.1 (2) any suppository dosage form containing amobarbital, secobarbital, pentobarbital, or
286.2 any salt of any of these drugs and approved by the food and drug administration for marketing
286.3 only as a suppository;

286.4 (3) any substance which contains any quantity of a derivative of barbituric acid, or any
286.5 salt of a derivative of barbituric acid, except those substances which are specifically listed
286.6 in other schedules;

286.7 (4) any drug product containing gamma hydroxybutyric acid, including its salts, isomers,
286.8 and salts of isomers, for which an application is approved under section 505 of the federal
286.9 Food, Drug, and Cosmetic Act;

286.10 (5) any of the following substances:

286.11 (i) chlorhexadol;
286.12 (ii) ketamine, its salts, isomers and salts of isomers;

286.13 (iii) lysergic acid;

286.14 (iv) lysergic acid amide;

286.15 (v) methyprylon;

286.16 (vi) sulfondiethylmethane;

286.17 (vii) sulfonenthylmethane;

286.18 (viii) sulfonmethane;

286.19 (ix) tiletamine and zolazepam and any salt thereof;

286.20 (x) embutramide;

286.21 (xi) Perampanel [2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-Dihydropyridin-3-yl)
286.22 benzonitrile].

286.23 (d) Nalorphine.

286.24 (e) Narcotic drugs. Unless specifically excepted or unless listed in another schedule,
286.25 any material, compound, mixture, or preparation containing any of the following narcotic
286.26 drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities
286.27 as follows:

286.28 (1) not more than 1.80 grams of codeine per 100 milliliters or not more than 90 milligrams
286.29 per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;

287.1 (2) not more than 1.80 grams of codeine per 100 milliliters or not more than 90 milligrams
287.2 per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic
287.3 amounts;

285.20 (2) any suppository dosage form containing amobarbital, secobarbital, pentobarbital, or
285.21 any salt of any of these drugs and approved by the food and drug administration for marketing
285.22 only as a suppository;

285.23 (3) any substance which contains any quantity of a derivative of barbituric acid, or any
285.24 salt of a derivative of barbituric acid, except those substances which are specifically listed
285.25 in other schedules;

285.26 (4) any drug product containing gamma hydroxybutyric acid, including its salts, isomers,
285.27 and salts of isomers, for which an application is approved under section 505 of the federal
285.28 Food, Drug, and Cosmetic Act;

285.29 (5) any of the following substances:

285.30 (i) chlorhexadol;
285.31 (ii) ketamine, its salts, isomers and salts of isomers;

286.1 (iii) lysergic acid;

286.2 (iv) lysergic acid amide;

286.3 (v) methyprylon;

286.4 (vi) sulfondiethylmethane;

286.5 (vii) sulfonenthylmethane;

286.6 (viii) sulfonmethane;

286.7 (ix) tiletamine and zolazepam and any salt thereof;

286.8 (x) embutramide;

286.9 (xi) Perampanel [2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-Dihydropyridin-3-yl)
286.10 benzonitrile].

286.11 (d) Nalorphine.

286.12 (e) Narcotic drugs. Unless specifically excepted or unless listed in another schedule,
286.13 any material, compound, mixture, or preparation containing any of the following narcotic
286.14 drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities
286.15 as follows:

286.16 (1) not more than 1.80 grams of codeine per 100 milliliters or not more than 90 milligrams
286.17 per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;

286.18 (2) not more than 1.80 grams of codeine per 100 milliliters or not more than 90 milligrams
286.19 per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic
286.20 amounts;

287.4 (3) not more than 1.80 grams of dihydrocodeine per 100 milliliters or not more than 90
287.5 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized
287.6 therapeutic amounts;

287.7 (4) not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than
287.8 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized
287.9 therapeutic amounts;

287.10 (5) not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not
287.11 more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients
287.12 in recognized therapeutic amounts;

287.13 (6) not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with
287.14 one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

287.15 (f) Anabolic steroids, human growth hormone, and chorionic gonadotropin.

287.16 (1) Anabolic steroids, for purposes of this subdivision, means any drug or hormonal
287.17 substance, chemically and pharmacologically related to testosterone, other than estrogens,
287.18 progestins, corticosteroids, and dehydroepiandrosterone, and includes:

287.19 (i) 3[beta],17[beta]-dihydroxy-5[alpha]-androstane;

287.20 (ii) 3[alpha],17[beta]-dihydroxy-5[alpha]-androstane;

287.21 (iii) androstanedione (5[alpha]-androstan-3,17-dione);

287.22 (iv) 1-androstenediol (3[beta],17[beta]-dihydroxy-5[alpha]-androst-1-ene);

287.23 (v) 3[alpha],17[beta]-dihydroxy-5[alpha]-androst-1-ene;

287.24 (vi) 4-androstenediol (3[beta],17[beta]-dihydroxy-androst-4-ene);

287.25 (vii) 5-androstenediol (3[beta],17[beta]-dihydroxy-androst-5-ene);

287.26 (viii) 1-androstenedione (5[alpha]-androst-1-en-3,17-dione);

287.27 (ix) 4-androstenedione (androst-4-en-3,17-dione);

287.28 (x) 5-androstenedione (androst-5-en-3,17-dione);

287.29 (xi) bolasterone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one);

287.30 (xii) boldenone (17[beta]-hydroxyandrost-1,4-diene-3-one);

288.1 (xiii) boldione (androsta-1,4-diene-3,17-dione);

288.2 (xiv) calusterone (7[beta],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one);

288.3 (xv) clostebol (4-chloro-17[beta]-hydroxyandrost-4-en-3-one);

286.21 (3) not more than 1.80 grams of dihydrocodeine per 100 milliliters or not more than 90
286.22 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized
286.23 therapeutic amounts;

286.24 (4) not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than
286.25 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized
286.26 therapeutic amounts;

286.27 (5) not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not
286.28 more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients
286.29 in recognized therapeutic amounts;

286.30 (6) not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with
286.31 one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

287.1 (f) Anabolic steroids, human growth hormone, and chorionic gonadotropin.

287.2 (1) Anabolic steroids, for purposes of this subdivision, means any drug or hormonal
287.3 substance, chemically and pharmacologically related to testosterone, other than estrogens,
287.4 progestins, corticosteroids, and dehydroepiandrosterone, and includes:

287.5 (i) 3[beta],17[beta]-dihydroxy-5[alpha]-androstane;

287.6 (ii) 3[alpha],17[beta]-dihydroxy-5[alpha]-androstane;

287.7 (iii) androstanedione (5[alpha]-androstan-3,17-dione);

287.8 (iv) 1-androstenediol (3[beta],17[beta]-dihydroxy-5[alpha]-androst-1-ene);

287.9 (v) 3[alpha],17[beta]-dihydroxy-5[alpha]-androst-1-ene;

287.10 (vi) 4-androstenediol (3[beta],17[beta]-dihydroxy-androst-4-ene);

287.11 (vii) 5-androstenediol (3[beta],17[beta]-dihydroxy-androst-5-ene);

287.12 (viii) 1-androstenedione (5[alpha]-androst-1-en-3,17-dione);

287.13 (ix) 4-androstenedione (androst-4-en-3,17-dione);

287.14 (x) 5-androstenedione (androst-5-en-3,17-dione);

287.15 (xi) bolasterone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one);

287.16 (xii) boldenone (17[beta]-hydroxyandrost-1,4-diene-3-one);

287.17 (xiii) boldione (androsta-1,4-diene-3,17-dione);

287.18 (xiv) calusterone (7[beta],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one);

287.19 (xv) clostebol (4-chloro-17[beta]-hydroxyandrost-4-en-3-one);

| | | | |
|--------|--|--------|--|
| 288.4 | (xvi) dehydrochloromethyltestosterone | 287.20 | (xvi) dehydrochloromethyltestosterone |
| 288.5 | (4-chloro-17[beta]-hydroxy-17[alpha]-methylandrost-1,4-dien-3-one); | 287.21 | (4-chloro-17[beta]-hydroxy-17[alpha]-methylandrost-1,4-dien-3-one); |
| 288.6 | (xvii) desoxymethyltestosterone (17[alpha]-methyl-5[alpha]-androst-2-en-17[beta]-ol); | 287.22 | (xvii) desoxymethyltestosterone (17[alpha]-methyl-5[alpha]-androst-2-en-17[beta]-ol); |
| 288.7 | (xviii) [delta]1-dihydrotestosterone- (17[beta]-hydroxy-5[alpha]-androst-1-en-3-one); | 287.23 | (xviii) [delta]1-dihydrotestosterone- (17[beta]-hydroxy-5[alpha]-androst-1-en-3-one); |
| 288.8 | (xix) 4-dihydrotestosterone (17[beta]-hydroxy-androstan-3-one); | 287.24 | (xix) 4-dihydrotestosterone (17[beta]-hydroxy-androstan-3-one); |
| 288.9 | (xx) drostanolone (17[beta]hydroxy-2[alpha]-methyl-5[alpha]-androstan-3-one); | 287.25 | (xx) drostanolone (17[beta]hydroxy-2[alpha]-methyl-5[alpha]-androstan-3-one); |
| 288.10 | (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-hydroxyestr-4-ene); | 287.26 | (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-hydroxyestr-4-ene); |
| 288.11 | (xxii) fluoxymesterone | 287.27 | (xxii) fluoxymesterone |
| 288.12 | (9-fluoro-17[alpha]-methyl-11[beta],17[beta]-dihydroxyandrost-4-en-3-one); | 287.28 | (9-fluoro-17[alpha]-methyl-11[beta],17[beta]-dihydroxyandrost-4-en-3-one); |
| 288.13 | (xxiii) formebolone | 288.1 | (xxiii) formebolone |
| 288.14 | (2-formyl-17[alpha]-methyl-11[alpha],17[beta]-dihydroxyandrost-1,4-dien-3-one); | 288.2 | (2-formyl-17[alpha]-methyl-11[alpha],17[beta]-dihydroxyandrost-1,4-dien-3-one); |
| 288.15 | (xxiv) furazabol | 288.3 | (xxiv) furazabol |
| 288.16 | (17[alpha]-methyl-17[beta]-hydroxyandrostano[2,3-c]-furazan)13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one; | 288.4 | (17[alpha]-methyl-17[beta]-hydroxyandrostano[2,3-c]-furazan)13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one; |
| 288.17 | | 288.5 | |
| 288.18 | (xxv) 4-hydroxytestosterone (4,17[beta]-dihydroxyandrost-4-en-3-one); | 288.6 | (xxv) 4-hydroxytestosterone (4,17[beta]-dihydroxyandrost-4-en-3-one); |
| 288.19 | (xxvi) 4-hydroxy-19-nortestosterone (4,17[beta]-dihydroxyestr-4-en-3-one); | 288.7 | (xxvi) 4-hydroxy-19-nortestosterone (4,17[beta]-dihydroxyestr-4-en-3-one); |
| 288.20 | (xxvii) mestanolone (17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androstan-3-one); | 288.8 | (xxvii) mestanolone (17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androstan-3-one); |
| 288.21 | (xxviii) mesterolone (1[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androstan-3-one); | 288.9 | (xxviii) mesterolone (1[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androstan-3-one); |
| 288.22 | (xxix) methandienone (17[alpha]-methyl-17[beta]-hydroxyandrost-1,4-dien-3-one); | 288.10 | (xxix) methandienone (17[alpha]-methyl-17[beta]-hydroxyandrost-1,4-dien-3-one); |
| 288.23 | (xxx) methandriol (17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-5-ene); | 288.11 | (xxx) methandriol (17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-5-ene); |
| 288.24 | (xxxi) methasterone (2 alpha-17 alpha-dimethyl-5 alpha-androstan-17beta-ol-3-one); | 288.12 | (xxxi) methasterone (2 alpha-17 alpha-dimethyl-5 alpha-androstan-17beta-ol-3-one); |
| 288.25 | (xxxii) methenolone (1-methyl-17[beta]-hydroxy-5[alpha]-androst-1-en-3-one); | 288.13 | (xxxii) methenolone (1-methyl-17[beta]-hydroxy-5[alpha]-androst-1-en-3-one); |
| 288.26 | (xxxiii) 17[alpha]-methyl-3[beta],17[beta]-dihydroxy-5[alpha]-androstane; | 288.14 | (xxxiii) 17[alpha]-methyl-3[beta],17[beta]-dihydroxy-5[alpha]-androstane; |
| 288.27 | (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy-5[alpha]-androstane; | 288.15 | (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy-5[alpha]-androstane; |
| 288.28 | (xxxv) 17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-4-ene; | 288.16 | (xxxv) 17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-4-ene; |
| 289.1 | (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone | 288.17 | (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone |
| 289.2 | (17[alpha]-methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one); | 288.18 | (17[alpha]-methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one); |
| 289.3 | (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9(10)-dien-3-one); | 288.19 | (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9(10)-dien-3-one); |
| 289.4 | (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9,11-trien-3-one); | 288.20 | (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9,11-trien-3-one); |
| 289.5 | (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]-hydroxyandrost-4-en-3-one); | 288.21 | (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]-hydroxyandrost-4-en-3-one); |

| | | | |
|--------|--|--------|--|
| 289.6 | (xl) mibolerone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyestr-4-en-3-one); | 288.22 | (xl) mibolerone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyestr-4-en-3-one); |
| 289.7 | (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone | 288.23 | (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone |
| 289.8 | (17[beta]-hydroxy-17[alpha]-methyl-5[alpha]-androst-1-en-3-one); | 288.24 | (17[beta]-hydroxy-17[alpha]-methyl-5[alpha]-androst-1-en-3-one); |
| 289.9 | (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one); | 288.25 | (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one); |
| 289.10 | (xliii) 19-nor-4-androstenediol (3[beta],17[beta]-dihydroxyestr-4-ene; | 288.26 | (xliii) 19-nor-4-androstenediol (3[beta],17[beta]-dihydroxyestr-4-ene; |
| 289.11 | (xliv) 3[alpha],17[beta]-dihydroxyestr-4-ene); 19-nor-5-androstenediol | 288.27 | (xliv) 3[alpha],17[beta]-dihydroxyestr-4-ene); 19-nor-5-androstenediol |
| 289.12 | (3[beta],17[beta]-dihydroxyestr-5-ene; | 288.28 | (3[beta],17[beta]-dihydroxyestr-5-ene; |
| 289.13 | (xlv) 3[alpha],17[beta]-dihydroxyestr-5-ene); | 288.29 | (xlv) 3[alpha],17[beta]-dihydroxyestr-5-ene); |
| 289.14 | (xlvi) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione); | 289.1 | (xlvi) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione); |
| 289.15 | (xlvii) 19-nor-5-androstenedione (estr-5-en-3,17-dione); | 289.2 | (xlvii) 19-nor-5-androstenedione (estr-5-en-3,17-dione); |
| 289.16 | (xlviii) norbolethone (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4-en-3-one); | 289.3 | (xlviii) norbolethone (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4-en-3-one); |
| 289.17 | (xlix) norclostebol (4-chloro-17[beta]-hydroxyestr-4-en-3-one); | 289.4 | (xlix) norclostebol (4-chloro-17[beta]-hydroxyestr-4-en-3-one); |
| 289.18 | (l) norethandrolone (17[alpha]-ethyl-17[beta]-hydroxyestr-4-en-3-one); | 289.5 | (l) norethandrolone (17[alpha]-ethyl-17[beta]-hydroxyestr-4-en-3-one); |
| 289.19 | (li) normethandrolone (17[alpha]-methyl-17[beta]-hydroxyestr-4-en-3-one); | 289.6 | (li) normethandrolone (17[alpha]-methyl-17[beta]-hydroxyestr-4-en-3-one); |
| 289.20 | (lii) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-2-oxa-5[alpha]-androstan-3-one); | 289.7 | (lii) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-2-oxa-5[alpha]-androstan-3-one); |
| 289.21 | (liii) oxymesterone (17[alpha]-methyl-4,17[beta]-dihydroxyandrost-4-en-3-one); | 289.8 | (liii) oxymesterone (17[alpha]-methyl-4,17[beta]-dihydroxyandrost-4-en-3-one); |
| 289.22 | (liv) oxymetholone | 289.9 | (liv) oxymetholone |
| 289.23 | (17[alpha]-methyl-2-hydroxymethylene-17[beta]-hydroxy-5[alpha]-androstan-3-one); | 289.10 | (17[alpha]-methyl-2-hydroxymethylene-17[beta]-hydroxy-5[alpha]-androstan-3-one); |
| 289.24 | (lv) prostanazol (17 beta-hydroxy-5 alpha-androstano[3,2-C]pyrazole; | 289.11 | (lv) prostanazol (17 beta-hydroxy-5 alpha-androstano[3,2-C]pyrazole; |
| 289.25 | (lvi) stanozolol | 289.12 | (lvi) stanozolol |
| 289.26 | (17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androst-2-eno[3,2-c]-pyrazole); | 289.13 | (17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androst-2-eno[3,2-c]-pyrazole); |
| 289.27 | (lvii) stenbolone (17[beta]-hydroxy-2-methyl-5[alpha]-androst-1-en-3-one); | 289.14 | (lvii) stenbolone (17[beta]-hydroxy-2-methyl-5[alpha]-androst-1-en-3-one); |
| 289.28 | (lviii) testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone); | 289.15 | (lviii) testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone); |
| 290.1 | (lix) testosterone (17[beta]-hydroxyandrost-4-en-3-one); | 289.16 | (lix) testosterone (17[beta]-hydroxyandrost-4-en-3-one); |
| 290.2 | (ix) tetrahydrogestrinone | 289.17 | (ix) tetrahydrogestrinone |
| 290.3 | (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4,9,11-trien-3-one); | 289.18 | (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4,9,11-trien-3-one); |
| 290.4 | (xi) trenbolone (17[beta]-hydroxyestr-4,9,11-trien-3-one); | 289.19 | (xi) trenbolone (17[beta]-hydroxyestr-4,9,11-trien-3-one); |
| 290.5 | (xii) any salt, ester, or ether of a drug or substance described in this paragraph. | 289.20 | (xii) any salt, ester, or ether of a drug or substance described in this paragraph. |

290.6 Anabolic steroids are not included if they are: (A) expressly intended for administration
 290.7 through implants to cattle or other nonhuman species; and (B) approved by the United States
 290.8 Food and Drug Administration for that use;

290.9 (2) Human growth hormones.

290.10 (3) Chorionic gonadotropin, except that a product containing chorionic gonadotropin is
 290.11 not included if it is:

290.12 (i) expressly intended for administration to cattle or other nonhuman species; and

290.13 (ii) approved by the United States Food and Drug Administration for that use.

290.14 (g) Hallucinogenic substances. Dronabinol (synthetic) in sesame oil and encapsulated
 290.15 in a soft gelatin capsule in a United States Food and Drug Administration approved product.

290.16 (h) Any material, compound, mixture, or preparation containing the following narcotic
 290.17 drug or its salt: buprenorphine.

290.18 (i) Marijuana, tetrahydrocannabinols, and synthetic cannabinoids. Unless specifically
 290.19 excepted or unless listed in another schedule, any natural or synthetic material, compound,
 290.20 mixture, or preparation that contains any quantity of the following substances, their analogs,
 290.21 isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence
 290.22 of the isomers, esters, ethers, or salts is possible:

290.23 (1) marijuana;

290.24 (2) tetrahydrocannabinols naturally contained in a plant of the genus Cannabis, except
 290.25 that tetrahydrocannabinols do not include any material, compound, mixture, or preparation
 290.26 that qualifies as industrial hemp as defined in section 18K.02, subdivision 3; synthetic
 290.27 equivalents of the substances contained in the cannabis plant or in the resinous extractives
 290.28 of the plant; or synthetic substances with similar chemical structure and pharmacological
 290.29 activity to those substances contained in the plant or resinous extract, including but not
 290.30 limited to 1 cis or trans tetrahydrocannabinol, 6 cis or trans tetrahydrocannabinol, and 3,4
 290.31 cis or trans tetrahydrocannabinol.

291.1 **EFFECTIVE DATE.** This section is effective the day following final enactment.

289.21 Anabolic steroids are not included if they are: (A) expressly intended for administration
 289.22 through implants to cattle or other nonhuman species; and (B) approved by the United States
 289.23 Food and Drug Administration for that use;

289.24 (2) Human growth hormones.

289.25 (3) Chorionic gonadotropin, except that a product containing chorionic gonadotropin is
 289.26 not included if it is:

289.27 (i) expressly intended for administration to cattle or other nonhuman species; and

289.28 (ii) approved by the United States Food and Drug Administration for that use.

290.1 (g) Hallucinogenic substances. Dronabinol (synthetic artificial) in sesame oil and
 290.2 encapsulated in a soft gelatin capsule in a United States Food and Drug Administration
 290.3 approved product.

290.4 (h) Any material, compound, mixture, or preparation containing the following narcotic
 290.5 drug or its salt: buprenorphine.

290.6 (i) Marijuana, tetrahydrocannabinols, and artificial cannabinoids. Unless specifically
 290.7 excepted or unless listed in another schedule, any natural or artificial material, compound,
 290.8 mixture, or preparation that contains any quantity of the following substances, their analogs,
 290.9 isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence
 290.10 of the isomers, esters, ethers, or salts is possible:

290.11 (1) marijuana;

290.12 (2) tetrahydrocannabinols naturally contained in a plant of the genus Cannabis, except
 290.13 that tetrahydrocannabinols do not include any material, compound, mixture, or preparation
 290.14 that qualifies as industrial hemp as defined in section 18K.02, subdivision 3; artificial
 290.15 equivalents of the substances contained in the cannabis plant or in the resinous extractives
 290.16 of the plant; or artificial substances with similar chemical structure and pharmacological
 290.17 activity to those substances contained in the plant or resinous extract, including but not
 290.18 limited to 1 cis or trans tetrahydrocannabinol, 6 cis or trans tetrahydrocannabinol, and 3,4
 290.19 cis or trans tetrahydrocannabinol.

290.20 **EFFECTIVE DATE.** This section is effective the day following final enactment.